Please login to the form below

Not currently logged in
Email:
Password:

Merck/ Parexel biosimilar alliance

Merck and Parexel have announced a strategic alliance to develop biosimilar candidates

Merck and Parexel have announced a strategic alliance to develop biosimilar candidates.

The agreement will see Parexel, a contract research organisation (CRO) with a focus on the biopharma industry, provide Merck  with access to global clinical development services for designated biosimilar candidates. The biosimilar candidates span several therapy areas.

A dedicated unit of Merck BioVentures,  the division of Merck focused on the development of biosimilars, will also be established within Parexel.

Financial details of the deal were not disclosed.

"Through this agreement, Merck BioVentures has secured broad strategic access to Parexel's proven biosimilar clinical development experience," said Michael Kamarck, president , Merck BioVentures. "This agreement positions Merck BioVentures for success with an industry leading partner that has the expertise and resources to conduct clinical development of our diverse portfolio of candidates to allow timely delivery of products to the marketplace."

Josef von Rickenbach, chairman and CEO of Parexel, was also positive about the agreement: "We are committed to working with Merck BioVentures to assist in advancing its biosimilar portfolio in this rapidly developing market segment for the benefit of patients worldwide."

13th January 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics